Scientists Identify Agent That Can Block Fibrosis of the Skin and Lungs PDF Print E-mail
Thursday, 31 May 2012 07:22
Researchers at the University of Pittsburgh School of Medicine have identified an agent that in lab tests protected the skin and lungs from fibrosis, a process that can ultimately end in organ failure and even death because the damaged tissue becomes scarred and can no longer function properly. The findings were published yesterday in Science Translational Medicine.

There are no effective therapies for life-threatening illnesses such as idiopathic pulmonary fibrosis and systemic sclerosis, which cause progressive organ scarring and failure, said senior author Carol A. Feghali-Bostwick, Ph.D., associate professor, Division of Pulmonary, Allergy and Critical Care Medicine, and co-Director of the Scleroderma Center, Pitt School of Medicine.

"It's estimated that tissue fibrosis contributes to 45 percent of all deaths in developed countries because organ failure is the final common pathway for numerous diseases," she said. "Identifying a way to stop this process from happening could have enormous impact on mortality and quality of life."

The research team evaluated E4, a piece of protein or peptide derived from endostatin, a component of collagen known for its inhibition of new blood vessel growth. In lab tests, healthy human skin cells that were treated to become fibrotic remained normal when E4 was present. The skin and lungs of mice were protected from cell death and tissue scarring by a single injection of E4 administered five or eight days after they were given the cancer drug bleomycin, which is known to induce fibrosis. The peptide also could reverse scarring that had already occurred, the researchers found.

In a unique approach, the investigators also tested E4 in human skin maintained in the laboratory to confirm it would be effective in treating fibrosis in a human tissue. E4 blocked new and ongoing fibrosis in human skin.

The agent might work by stalling the cross-linking of collagen needed to form thick scars, Dr. Feghali-Bostwick said. While the body naturally produces endostatin, it appears that it cannot make sufficient amounts to counteract fibrosis development in some diseases.

"This endostatin peptide passes two important hurdles that suggest it is a promising candidate drug for development for patients with idiopathic pulmonary fibrosis and systemic sclerosis" said Mark T. Gladwin, M.D., chief, Division of Pulmonary, Allergy and Critical Care Medicine at UPMC and Pitt. "It reverses established disease in animal models and it reverses fibrosis in the human skin fibrosis model."

In a case of serendipity, the researchers discovered E4 while exploring the process of fibrosis. Post-doctoral fellow and study co-author Yukie Yamaguchi, M.D., Ph.D., was conducting some experiments with proteins thought to facilitate the scarring process.

"Dr. Yamaguchi showed me the tests that showed endostatin wasn't working to increase fibrosis, but in fact shut it down," Dr. Feghali-Bostwick said. "It was the opposite of what we expected and I was very excited about our finding. As Louis Pasteur once said, 'chance favors the prepared mind.'"

Source: MedicalExpress (2012), "Scientists identify agent that can block fibrosis of skin, lungs";
 
More articles :

» Finger Ulcers Still a Problem in Scleroderma

A significant number of patients with systemic sclerosis develop , greatly increasing their disease burden and the likelihood of complications, researchers reported here.For instance, 29.8% of patients with one or more digital ulcers developed...

» Gene Profiling of Scleroderma Skin Reveals Robust Signatures of Disease...

Humphrey Gardner, Jeffrey R. Shearstone, Raj Bandaru, Tom Crowell, Matthew Lynes, Maria Trojanowska, Jaspreet Pannu, Edwin Smith, Stefania Jablonska, Maria Blaszczyk, Filemon K. Tan, and Maureen D. MayesARTHRITIS & RHEUMATISMVol. 54, No. 6, June...

» Vascular Changes in Bleomycin-Induced Scleroderma

Toshiyuki Yamamoto and Ichiro KatayamaDepartment of Dermatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, JapanDepartment of Dermatology, Osaka University, Yamadaoka 2-2, Suita, Osaka 565-0871, JapanReceived 6 June 2011;...

» Clinical Significance of Antibodies to Ro52/TRIM21 in Systemic Sclerosis

Marie Hudson, Janet Pope, Michael Mahler, Solene Tatibouet, Russell Steele, Murray Baron, Canadian Scleroderma Research Group (csrg) and Marvin J FritzlerArthritis Research & Therapy 2012, 14:R50 doi:10.1186/ar3763Published: 6 March...

» Systemic Sclerosis Sine Scleroderma

HADI POORMOGHIM, MARY LUCAS, NOREEN FERTIG, and THOMAS A. MEDSGER, JR.ARTHRITIS & RHEUMATISM Vol. 43, No. 2, February 2000, pp 444–451 © 2000, American College of RheumatologyObjectiveTo describe the demographic, clinical, and laboratory...

» A Brief History of Scleroderma

While scleroderma may not be very well known to the average person, investigation reveals it has been around for a long time.Classical ReferencesCases of skin disease similar to scleroderma may be found in the writings of Hippocrates as far back as...